← Back to Search

Cancer Vaccine

Mature dendritic cell (DC) vaccine for Melanoma

Phase 1
Waitlist Available
Led By Gerald P Linette, MD, PhD
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10-28 days after the third vaccine through study completion approximately 30 weeks after the first dc vaccine
Awards & highlights

Study Summary

This trial is testing a method of using dendritic cells to create a vaccine against melanoma.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10-28 days after the third vaccine through study completion approximately 30 weeks after the first dc vaccine
This trial's timeline: 3 weeks for screening, Varies for treatment, and 10-28 days after the third vaccine through study completion approximately 30 weeks after the first dc vaccine for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Immune response measuring increased numbers of peptide specific T cells as calculated by the tetramer assay.
Secondary outcome measures
Clinical response
Safety and side effects of vaccine per CTCAE 4.0
Time to progression

Trial Design

1Treatment groups
Experimental Treatment
Group I: Mature dendritic cell (DC) vaccineExperimental Treatment3 Interventions
Mature DC 7.5-15 million/peptide given day 1, every six weeks for 2 doses followed by standard of care anti PD-1 therapy
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pembrolizumab
2017
Completed Phase 2
~2010

Find a Location

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor
2,000 Previous Clinical Trials
42,880,076 Total Patients Enrolled
8 Trials studying Melanoma
4,612 Patients Enrolled for Melanoma
Gerald P Linette, MD, PhDPrincipal InvestigatorUniversity of Pennsylvania
1 Previous Clinical Trials
4 Total Patients Enrolled
1 Trials studying Melanoma
4 Patients Enrolled for Melanoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Dendritic Cell Vaccination in Patients With Advanced Melanoma
2017. "Dendritic Cell Vaccination in Patients With Advanced Melanoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03092453.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top